Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Am J Trop Med Hyg ; 108(4): 768-776, 2023 04 05.
Artigo em Inglês | MEDLINE | ID: mdl-36780896

RESUMO

Maternal malaria and infections during pregnancy are risk factors for fetal growth restriction. We assessed the impact of preventive treatment in pregnancy on maternal malaria and fetal growth. Between 2003 and 2006, we enrolled 1,320 pregnant Malawian women, 14-26 gestation weeks, in a randomized trial and treated them with two doses of sulfadoxine-pyrimethamine (SP, control) at enrollment and between 28-34 gestation weeks; with monthly SP from enrollment until 37 gestation weeks; or with monthly SP and azithromycin twice, at enrollment and between 28 and 34 gestation weeks (AZI-SP). Participants were seen at 4-week intervals until 36 completed gestation weeks and weekly thereafter. At each visit, we collected dried blood spots for real-time polymerase chain reaction diagnosing of malaria parasitemia and, in a random subgroup of 341 women, we measured fetal biparietal diameter and femur length with ultrasound. For the monthly SP versus the control group, the odds ratios (OR) (95% CI) of malaria parasitemia during the second, third, and both trimesters combined were 0.79 (0.46-1.37), 0.58 (0.37-0.92), and 0.64 (0.42-0.98), respectively. The corresponding ORs for the AZI-SP versus control group were 0.47 (0.26-0.84), 0.51 (0.32-0.81), and 0.50 (0.32-0.76), respectively. Differences between the AZI-SP and the monthly SP groups were not statistically significant. The interventions did not affect fetal biparietal diameter and femur length growth velocity. The results suggest that preventive maternal treatment with monthly SP reduced malaria parasitemia during pregnancy in Malawi and that the addition of azithromycin did not provide much additional antimalarial effect.


Assuntos
Antimaláricos , Malária , Complicações Parasitárias na Gravidez , Feminino , Gravidez , Humanos , Azitromicina/uso terapêutico , Parasitemia/tratamento farmacológico , Complicações Parasitárias na Gravidez/prevenção & controle , Pirimetamina/uso terapêutico , Malária/prevenção & controle , Antimaláricos/uso terapêutico , Combinação de Medicamentos , Desenvolvimento Fetal
2.
Arch Dis Child ; 107(4): 323-328, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-34479861

RESUMO

OBJECTIVE: To assess whether intermittent preventive treatment of pregnant women (IPTp) with sulfadoxine-pyrimethamine (SP) and azithromycin (AZI) in a malaria-endemic area leads to sustained gains in linear growth and development in their offspring. DESIGN: Follow-up study of a randomised trial. SETTING: Mangochi District in rural southern Malawi. PARTICIPANTS: 1320 pregnant women and their offspring. INTERVENTIONS: IPTp monthly with SP and twice with AZI (AZI-SP group), monthly with SP but no AZI (monthly SP), or twice with SP (control). No intervention was given to children. MAIN OUTCOME MEASURES: Cognitive performance using Raven's Coloured Progressive Matrices (CPM) at 13 years of age; mean height and height-for-age Z-score (HAZ), cumulative incidence and prevalence of stunting (HAZ <-2); weight, body mass index, mid-upper-arm circumference and head circumference. RESULTS: At approximately 13 years of age, the mean CPM score was 14.3 (SD 3.8, range 6-29, maximum 36), with no differences between groups. Children in the AZI-SP group were on average 0.4 cm (95% CI -0.9 to 1.7, p=0.6) taller than those in the control group. For cumulative incidence of stunting, the HR in the AZI-SP group was 0.72 (95% CI 0.61 to 0.84, p<0.001) compared with the control and 0.76 (95% CI 0.65 to 0.90, p<0.001) compared with the monthly SP groups. There was no intergroup difference in stunting prevalence or anthropometric measurements. CONCLUSIONS: In rural Malawi, maternal intensified infection control during pregnancy reduces offspring's cumulative incidence of ever being stunted by 13 years of age. In this study, there was no evidence of a positive impact on cognitive performance. TRIAL REGISTRATION NUMBER: NCT00131235.


Assuntos
Antimaláricos , Complicações Parasitárias na Gravidez , Antibacterianos/uso terapêutico , Antimaláricos/uso terapêutico , Azitromicina , Criança , Combinação de Medicamentos , Feminino , Seguimentos , Transtornos do Crescimento/tratamento farmacológico , Transtornos do Crescimento/epidemiologia , Transtornos do Crescimento/prevenção & controle , Humanos , Gravidez , Complicações Parasitárias na Gravidez/tratamento farmacológico , Complicações Parasitárias na Gravidez/epidemiologia , Complicações Parasitárias na Gravidez/prevenção & controle
3.
PLoS One ; 14(5): e0216536, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31063503

RESUMO

AIM: Intermittent preventive treatment in pregnancy (IPTp) with azithromycin and monthly sulfadoxine-pyrimethamine increased the mean child weight, mid-upper arm and head circumference at four weeks of age in a rural low-income setting. Now we assess for how long these gains were sustained during 0-5 years of age. METHODS: We enrolled 1320 pregnant Malawian women in a randomized trial and treated them with two doses of sulfadoxine-pyrimethamine (control) or monthly sulfadoxine-pyrimethamine as IPTp against malaria, or monthly sulfadoxine-pyrimethamine and two doses of azithromycin (AZI-SP) as IPTp against malaria and reproductive tract infections. Child weight, mid-upper arm circumference, head circumference and weight-for-height Z-score were recorded at one, six, 12, 24, 36, 48, and 60 months. RESULTS: Throughout follow-up, the mean child weight was approximately 100 g higher (difference in means 0.12 kg, 95% CI 0.04-0.20, P = 0.003 at one month; 0.19 kg, 95% CI 0.05-0.33, P = 0.007, at six months), mean head circumference 2 mm larger (0.3 cm, 95% CI 0.1 to 0.5, P = 0.004 at one month) and the cumulative incidence of underweight by five years of age was lower (hazard ratio 0.74, 95% CI 0.60 to 0.90, P = 0.002) in the AZI-SP group than in the control group. The 2 mm difference in the mean mid-upper arm circumference at one month (0.2 cm, 95% CI 0.0 to 0.3, P = 0.007) disappeared after three years of age. There was no difference in mean weight-for-height Z-score at any time point. CONCLUSION: In Malawi, IPTp with azithromycin and monthly sulfadoxine-pyrimethamine has a modest, 3-5-year positive impact on child weight, mid-upper arm circumference and head circumference, but not on weight-for-height Z-score.


Assuntos
Braço/anatomia & histologia , Azitromicina/administração & dosagem , Peso ao Nascer/efeitos dos fármacos , Cabeça/anatomia & histologia , Malária/prevenção & controle , Pirimetamina/administração & dosagem , Infecções Respiratórias/prevenção & controle , Sulfadoxina/administração & dosagem , Adulto , Antibacterianos/administração & dosagem , Antimaláricos/administração & dosagem , Criança , Pré-Escolar , Combinação de Medicamentos , Feminino , Seguimentos , Humanos , Incidência , Lactente , Recém-Nascido , Malária/epidemiologia , Malaui , Masculino , Gravidez , Complicações Infecciosas na Gravidez/epidemiologia , Complicações Infecciosas na Gravidez/prevenção & controle , Complicações Parasitárias na Gravidez/epidemiologia , Complicações Parasitárias na Gravidez/prevenção & controle , Infecções Respiratórias/epidemiologia
4.
Pediatrics ; 141(3)2018 03.
Artigo em Inglês | MEDLINE | ID: mdl-29472491

RESUMO

BACKGROUND AND OBJECTIVES: We showed earlier that presumptive infection treatment in pregnancy reduced the prevalence of neonatal stunting in a rural low-income setting. In this article, we assess how these gains were sustained and reflected in childhood growth, development, and mortality. METHODS: We enrolled 1320 pregnant Malawian women in a randomized trial and treated them for malaria and other infections with either 2 doses of sulfadoxine-pyrimethamine (SP) (control), monthly SP, or monthly sulfadoxine-pyrimethamine and 2 doses of azithromycin (AZI-SP). Child height or length and mortality were recorded at 1, 6, 12, 24, 36, 48, and 60 months and development at 60 months by using Griffith's Mental Development Scales. RESULTS: Throughout follow-up, the mean child length was 0.4 to 0.7 cm higher (P < .05 at 1-12 months), the prevalence of stunting was 6 to 11 percentage points lower (P < .05 at 12-36 months), and the 5-year cumulative incidence of stunting was 13 percentage points lower (hazard ratio: 0.70, 95% confidence interval [CI]: 0.60 to 0.83, P < .001) in the AZI-SP group than in the control group. The mean developmental score was 3.8 points higher in the AZI-SP group than in the control group (95% CI: 1.1 to 6.4, P = .005). Total mortality during pregnancy and childhood was 15.3%, 15.1%, and 13.1% (P = .60) in the control, monthly SP, and AZI-SP groups, respectively. Postneonatal mortality (secondary outcome) was 5.5%, 3.3%, and 1.9%, respectively (risk ratio of AZI-SP versus control: 0.34, 95% CI: 0.15 to 0.76, P = .008). CONCLUSIONS: Provision of AZI-SP rather than 2 doses of SP during pregnancy reduced the incidence of stunting in childhood. AZI-SP during pregnancy also had a positive effect on child development and may have reduced postneonatal mortality.


Assuntos
Desenvolvimento Infantil , Saúde da Criança , Mortalidade da Criança , Complicações Infecciosas na Gravidez/tratamento farmacológico , Adulto , Antibacterianos/uso terapêutico , Antimaláricos/uso terapêutico , Azitromicina/uso terapêutico , Pré-Escolar , Combinação de Medicamentos , Feminino , Morte Fetal , Seguimentos , Transtornos do Crescimento/epidemiologia , Humanos , Incidência , Lactente , Malária/tratamento farmacológico , Malaui , Gravidez , Complicações Parasitárias na Gravidez/tratamento farmacológico , Prevalência , Pirimetamina/uso terapêutico , População Rural , Sulfadoxina/uso terapêutico
5.
Am J Clin Nutr ; 99(2): 296-301, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24225354

RESUMO

BACKGROUND: To monitor weight gain during pregnancy and assess its relation with perinatal health outcomes, both unconditional (cross-sectional) and conditional (longitudinal) standards of maternal weight are needed. OBJECTIVE: This study aimed to develop and validate unconditional and conditional maternal weight standards for use in Malawi, Africa. DESIGN: Longitudinal data were drawn from an antenatal care intervention study conducted in Malawi. Participants were selected for this analysis if they had a healthy profile defined by body mass index and infectious disease measures and delivered healthy singletons defined by birth weight, gestational age, and neonatal survival status. A total of 1733 measurements from 358 women were randomly split to form development and validation samples. RESULTS: Unconditional and conditional standards were developed and validated. An electronic spreadsheet implements the calculations. Weight gain during pregnancy was substantially slower in this cohort than the US Institute of Medicine recommendation. The percentiles increased linearly; therefore, the use of the conditional standards is robust to inaccuracy in gestational age estimates. CONCLUSION: The standards can facilitate researchers and clinicians to examine maternal weight and weight gain and estimate their associations with pregnancy outcomes in Malawi. This trial was registered at www.clinicaltrials.gov as NCT00131235.


Assuntos
Gravidez , Aumento de Peso/fisiologia , Adolescente , Peso ao Nascer , Índice de Massa Corporal , Ensaios Clínicos Fase III como Assunto , Estudos Transversais , Bases de Dados Factuais , Feminino , Idade Gestacional , Humanos , Modelos Lineares , Estudos Longitudinais , Malaui/epidemiologia , Modelos Biológicos , Resultado da Gravidez , Ensaios Clínicos Controlados Aleatórios como Assunto , Padrões de Referência , Reprodutibilidade dos Testes
6.
Trop Med Int Health ; 18(4): 386-97, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23432801

RESUMO

OBJECTIVE: To examine the potential to reduce foetal and neonatal growth faltering through intermittent preventive treatment in pregnancy (IPTp) of malaria and reproductive tract infections with monthly sulphadoxine-pyrimethamine (SP), alone or with two doses of azithromycin. METHODS: We enrolled 1320 women with uncomplicated second trimester pregnancies into a randomised, partially placebo controlled, outcome assessor-blinded clinical trial in Malawi. The participants received either two doses of SP (control), SP monthly (monthly SP) or SP monthly and azithromycin (1 g) twice (AZI-SP). Newborn size was measured within two days of birth and infant growth at four weeks of age. RESULTS: Babies in the AZI-SP group were on average (95% CI) 140 g (70-200) heavier at birth and 0.6 cm (0.2-0.9) longer at four weeks of age than control group babies. Corresponding differences between the monthly SP and control groups were 80 g (20-140) and 0.3 cm (-0.0 to 0.6). Compared with controls, babies in the AZI-SP group had a relative risk of 0.61 (0.40-0.93) for low birthweight, 0.60 (0.44-0.81) for stunting and 0.48 (0.29-0.79) for underweight at four weeks of age. Corresponding differences were similar but smaller between the monthly SP and control groups. CONCLUSIONS: An IPTp regimen with monthly SP given to all pregnant women is likely to increase mean birthweight and length at four weeks of age in malaria holoendemic areas. Adding azithromycin to the regimen appears to offer further benefits in reducing foetal and neonatal growth faltering.


Assuntos
Azitromicina/administração & dosagem , Peso ao Nascer/efeitos dos fármacos , Desenvolvimento Fetal/efeitos dos fármacos , Malária Falciparum/prevenção & controle , Complicações Parasitárias na Gravidez/prevenção & controle , Pirimetamina/administração & dosagem , Sulfadoxina/administração & dosagem , Adolescente , Adulto , Antibacterianos/administração & dosagem , Antimaláricos/administração & dosagem , Esquema de Medicação , Combinação de Medicamentos , Quimioterapia Combinada , Feminino , Humanos , Recém-Nascido , Malaui , Gravidez , Infecções do Sistema Genital/tratamento farmacológico , Adulto Jovem
7.
JAMA ; 309(6): 594-604, 2013 Feb 13.
Artigo em Inglês | MEDLINE | ID: mdl-23403684

RESUMO

IMPORTANCE: Intermittent preventive therapy with sulfadoxine-pyrimethamine to control malaria during pregnancy is used in 37 countries in sub-Saharan Africa, and 31 of those countries use the standard 2-dose regimen. However, 2 doses may not provide protection during the last 4 to 10 weeks of pregnancy, a pivotal period for fetal weight gain. OBJECTIVE: To perform a systematic review and meta-analysis of trials to determine whether regimens containing 3 or more doses of sulfadoxine-pyrimethamine for intermittent preventive therapy during pregnancy are associated with a higher birth weight or lower risk of low birth weight (LBW) (<2500 g) than standard 2-dose regimens. DATA SOURCES AND STUDY SELECTION: ISI Web of Knowledge, EMBASE, SCOPUS, PubMed, LILACS, the Malaria in Pregnancy Library, Cochrane CENTRAL, and trial registries from their inception to December 2012, without language restriction. Eligible studies included randomized and quasi-randomized trials of intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine monotherapy. DATA EXTRACTION: Data were independently abstracted by 2 investigators. Relative risk (RR), mean differences, and 95% CIs were calculated with random-effects models. RESULTS: Of 241 screened studies, 7 trials of 6281 pregnancies were included. The median birth weight in the 2-dose group was 2870 g (range, 2722-3239 g) and on average 56 g higher (95% CI, 29-83 g; I2 = 0%) in the ≥3-dose group. Three or more doses were associated with fewer LBW births (RR, 0.80; 95% CI, 0.69-0.94; I 2 = 0%), with a median LBW risk per 1000 women in the 2-dose group (assumed control group risk) of 167 per 1000 vs 134 per 1000 in the ≥3-dose group (absolute risk reduction, 33 per 1000 [95% CI, 10-52]; number needed to treat = 31). The association was consistent across a wide range of sulfadoxine-pyrimethamine resistance (0% to 96% dihydropteroate-synthase K540E mutations). There was no evidence of small-study bias. The ≥3-dose group had less placental malaria (RR, 0.51; 95% CI, 0.38-0.68; I 2 = 0%, in 6 trials, 63 vs 32 per 1000; absolute risk reduction, 31 per 1000 [95% CI, 20-39]). In primigravid plus secundigravid women, the risk of moderate to severe maternal anemia was lower in the ≥3-dose group (RR, 0.60; 95% CI, 0.36-0.99; I2 = 20%; in 6 trials, 36 vs 22 per 1000; absolute risk reduction, 14 per 1000 [95% CI, 0.4-23]). There were no differences in rates of serious adverse events. CONCLUSIONS AND RELEVANCE: Among pregnant women in sub-Saharan Africa, intermittent preventive therapy with 3 or more doses of sulfadoxine-pyrimethamine was associated with a higher birth weight and lower risk of LBW than the standard 2-dose regimens. These data provide support for the new WHO recommendations to provide at least 3 doses of intermittent preventive therapy during pregnancy at each scheduled antenatal care visit in the second and third trimester.


Assuntos
Antimaláricos/administração & dosagem , Recém-Nascido de Baixo Peso , Malária/prevenção & controle , Complicações Infecciosas na Gravidez/prevenção & controle , Pirimetamina/administração & dosagem , Sulfadoxina/administração & dosagem , África/epidemiologia , Esquema de Medicação , Combinação de Medicamentos , Feminino , Humanos , Recém-Nascido , Malária/epidemiologia , Gravidez , Complicações Infecciosas na Gravidez/epidemiologia , Risco
8.
Trop Med Int Health ; 18(2): 175-8, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23198734

RESUMO

In the context of an Intermittent preventive treatment (IPTp) trial for pregnant women in Malawi, Plasmodium falciparum samples from 85 women at enrollment and 35 women at delivery were genotyped for mutations associated with sulfadoxine-pyrimethamine resistance. The prevalence of the highly resistant haplotype with mutations at codons 51 and 108 of dihydrofolate reductase (dhfr) and codons 437 and 540 of dihydropteroate synthase (dhps) increased from 81% at enrollment to 100% at delivery (P = 0.01). Pregnant women who were smear-positive at enrollment were more likely to have P. falciparum parasitemia at delivery. These results lend support to concerns that IPTp use may lead to increased drug resistance in pregnant women during pregnancy and emphasise the importance of screening pregnant women for malaria parasites in areas with prevalent SP resistance even when they are already on IPTp.


Assuntos
Antimaláricos/uso terapêutico , Di-Hidropteroato Sintase/genética , Malária Falciparum/prevenção & controle , Mutação , Plasmodium falciparum/efeitos dos fármacos , Complicações Parasitárias na Gravidez/tratamento farmacológico , Tetra-Hidrofolato Desidrogenase/genética , DNA de Protozoário/genética , Combinação de Medicamentos , Resistência a Medicamentos , Feminino , Genótipo , Haplótipos , Humanos , Malária Falciparum/genética , Malaui , Plasmodium falciparum/genética , Reação em Cadeia da Polimerase , Gravidez , Complicações Parasitárias na Gravidez/genética , Pirimetamina/uso terapêutico , Sulfadoxina/uso terapêutico
9.
PLoS One ; 7(7): e41123, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22829919

RESUMO

BACKGROUND: New regimens for intermittent preventive treatment in pregnancy (IPTp) against malaria are needed as the effectiveness of the standard two-dose sulfadoxine-pyrimethamine (SP) regimen is under threat. Previous trials have shown that IPTp with monthly SP benefits HIV-positive primi- and secundigravidae, but there is no conclusive evidence of the possible benefits of this regimen to HIV-negative women, or to a population comprising of both HIV-positive and -negative women of different gravidities. METHODS: This study analyzed 484 samples collected at delivery as part of a randomized, partially placebo controlled clinical trial, conducted in rural Malawi between 2003 and 2007. The study included pregnant women regardless of their gravidity or HIV-infection status. The participants received SP twice (controls), monthly SP, or monthly SP and two doses of azithromycin (AZI-SP). The main outcome was the prevalence of peripheral Plasmodium falciparum malaria at delivery diagnosed with a real-time polymerase chain reaction (PCR) assay. FINDINGS: Overall prevalence of PCR-diagnosed peripheral P. falciparum malaria at delivery was 10.5%. Compared with the controls, participants in the monthly SP group had a risk ratio (95% CI) of 0.33 (0.17 to 0.64, P<0.001) and those in the AZI-SP group 0.23 (0.11 to 0.48, P<0.001) for malaria at delivery. When only HIV-negative participants were analyzed, the corresponding figures were 0.26 (0.12 to 0.57, P<0.001) for women in the monthly SP group, and 0.24 (0.11 to 0.53, P<0.001) for those in the AZI-SP group. CONCLUSIONS: Our results suggest that increasing the frequency of SP administration during pregnancy improves the efficacy against malaria at delivery among HIV-negative women, as well as a population consisting of both HIV-positive and -negative pregnant women of all gravidities, in a setting of relatively low but holoendemic malaria transmission, frequent use of bed nets and high SP resistance.


Assuntos
Antimaláricos/uso terapêutico , Azitromicina/uso terapêutico , Malária/tratamento farmacológico , Pirimetamina/uso terapêutico , Sulfadoxina/uso terapêutico , Adolescente , Adulto , Antimaláricos/administração & dosagem , Azitromicina/administração & dosagem , Esquema de Medicação , Combinação de Medicamentos , Feminino , Humanos , Masculino , Gravidez , Complicações Parasitárias na Gravidez/tratamento farmacológico , Pirimetamina/administração & dosagem , Sulfadoxina/administração & dosagem , Adulto Jovem
10.
PLoS One ; 7(1): e29874, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22299027

RESUMO

BACKGROUND: Antibodies towards placental-binding P. falciparum are thought to protect against pregnancy malaria; however, environmental factors may affect antibody development. METHODS AND FINDINGS: Using plasma from pregnant Malawian women, we measured IgG against placental-binding P. falciparum parasites by flow cytometry, and related results to intermittent preventive treatment (IPTp) regime, and bed net use. Bed net use was associated with decreased antibody levels at mid-pregnancy but not at 1 month post partum (1 mpp). At 1 mpp a more intensive IPTp regime was associated with decreased antibody levels in primigravidae, but not multigravidae. CONCLUSIONS/SIGNIFICANCE: Results suggest bed nets and IPTp regime influence acquisition of pregnancy-specific P. falciparum immunity.


Assuntos
Quimioprevenção , Malária Falciparum/imunologia , Malária Falciparum/terapia , Mosquiteiros , Plasmodium falciparum/imunologia , Complicações Parasitárias na Gravidez/imunologia , Complicações Parasitárias na Gravidez/terapia , Adolescente , Adulto , Anticorpos Antiprotozoários/sangue , Linhagem Celular , Quimioprevenção/métodos , Feminino , Humanos , Malária Falciparum/sangue , Malária Falciparum/epidemiologia , Mosquiteiros/estatística & dados numéricos , Parasitemia/epidemiologia , Periodicidade , Gravidez , Complicações Parasitárias na Gravidez/sangue , Complicações Parasitárias na Gravidez/epidemiologia , Estudos Soroepidemiológicos , Adulto Jovem
11.
Am J Trop Med Hyg ; 83(6): 1212-20, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21118924

RESUMO

Preterm delivery, which is associated with infections during pregnancy, is common in sub-Saharan Africa. We enrolled 1,320 pregnant women into a randomized, controlled trial in Malawi to study whether preterm delivery and low birth weight (LBW) incidence can be reduced by intermittent preventive treatment of maternal malaria and reproductive tract infections. The participants received either sulfadoxine-pyrimethamine (SP) twice (controls), monthly SP, or monthly SP and two doses of azithromycin (AZI-SP). The incidence of preterm delivery was 17.9% in controls, 15.4% in the monthly SP group (P = 0.32), and 11.8% in AZI-SP group (risk ratio = 0.66, P = 0.01). Compared with controls, those in AZI-SP group had a risk ratio of 0.61 (P = 0.02) for LBW. Incidence of serious adverse events was low in all groups. In conclusion, the incidence of preterm delivery and LBW can in some conditions be reduced by treating pregnant women with monthly SP and two azithromycin doses.


Assuntos
Azitromicina/administração & dosagem , Azitromicina/uso terapêutico , Nascimento Prematuro/prevenção & controle , Pirimetamina/administração & dosagem , Pirimetamina/uso terapêutico , Sulfadoxina/administração & dosagem , Sulfadoxina/uso terapêutico , Adolescente , Adulto , Esquema de Medicação , Combinação de Medicamentos , Feminino , Humanos , Recém-Nascido de Baixo Peso , Recém-Nascido , Malaui/epidemiologia , Gravidez , Complicações Parasitárias na Gravidez/tratamento farmacológico , Adulto Jovem
12.
Malar J ; 9: 269, 2010 Oct 06.
Artigo em Inglês | MEDLINE | ID: mdl-20925928

RESUMO

BACKGROUND: New diagnostic tools for malaria are required owing to the changing epidemiology of malaria, particularly among pregnant women in sub-Saharan Africa. Real-time PCR assays targeting Plasmodium falciparum lactate dehydrogenase (pfldh) gene may facilitate the identification of a high proportion of pregnant women with a P. falciparum parasitaemia below the threshold of microscopy. These molecular methods will enable further studies on the effects of these submicroscopic infections on maternal health and birth outcomes. METHODS: The pfldh real-time PCR assay and conventional microscopy were compared for the detection of P. falciparum from dried blood spots and blood smears collected from the peripheral blood of 475 Malawian women at delivery. A cycle threshold (Ct) of the real-time PCR was determined optimizing the sensitivity and specificity of the pfldh PCR assay compared to microscopy. A real-time PCR species-specific assay was applied to identify the contribution to malaria infections of three Plasmodium species (P. falciparum P. ovale and P. malariae) in 44 discordant smear and pfldh PCR assay results. RESULTS: Of the 475 women, P. falciparum was detected in 11 (2.3%) by microscopy and in 51 (10.7%) by real-time PCR; compared to microscopy, the sensitivity of real-time PCR was 90.9% and the specificity 91.2%. If a Ct value of 38 was used as a cut-off, specificity improved to 94.6% with no change in sensitivity. The real-time PCR species-specific assay detected P. falciparum alone in all but four samples: two samples were mixed infections with P. falciparum and P. malariae, one was a pure P. malariae infection and one was a pfldh PCR assay-positive/species-specific assay-negative sample. Of three P. malariae infections detected by microscopy, only one was confirmed by the species-specific assay. CONCLUSIONS: Although microscopy remains the most appropriate method for clinical malaria diagnosis in field settings, molecular diagnostics such as real-time PCR offer a more reliable means to detect malaria parasites, particularly at low levels. Determination of the possible contribution of these submicroscopic infections to poor birth outcomes and maternal health is critical. For future studies to investigate these effects, this pfldh real-time PCR assay offers a reliable detection method.


Assuntos
Malária/diagnóstico , Microscopia/métodos , Parasitologia/métodos , Plasmodium/isolamento & purificação , Reação em Cadeia da Polimerase/métodos , Complicações Infecciosas na Gravidez/diagnóstico , Adolescente , Adulto , África , Sangue/parasitologia , Dessecação , Feminino , Humanos , Recém-Nascido , L-Lactato Desidrogenase/genética , Malária/parasitologia , Malaui , Plasmodium/classificação , Gravidez , Proteínas de Protozoários/genética , Sensibilidade e Especificidade , Manejo de Espécimes/métodos , Fatores de Tempo , Adulto Jovem
13.
J Infect Dis ; 201(9): 1316-25, 2010 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-20350189

RESUMO

BACKGROUND: Plasmodium falciparum parasites that cause malaria in pregnancy express unique variant surface antigens (VSAs). Levels of immunoglobulin G (IgG) antibody to pregnancy-associated VSAs measured at delivery are gravidity dependent, and they have been associated with protection from disease. It is not known how these IgG responses develop in pregnant women receiving intermittent preventive treatment during pregnancy (IPTp) or whether IgG levels in early pregnancy predict pregnancy outcomes. METHODS: We performed longitudinal measurements of IgG antibody to VSAs by flow cytometric analysis of serum samples obtained from 549 Malawian women receiving IPTp. We examined fluctuations in IgG levels over time and associated the IgG levels noted at study enrollment with clinical outcomes. RESULTS: Levels of IgG antibody to pregnancy-associated VSAs were gravidity dependent. Overall, levels decreased while women were receiving IPTp, but the levels of the individuals were highly dynamic. Primigravidae developed low levels of pregnancy-specific IgG, which were often boosted during second pregnancies. The prevalence of parasites was low (8.4% at enrollment and 2.4% in late pregnancy). Antibody levels at enrollment did not predict birth weight, duration of gestation at delivery, or the maternal hemoglobin level in late pregnancy. CONCLUSION: Levels of IgG antibody to pregnancy-specific VSAs decrease during receipt of IPTp. Antibody levels in early pregnancy did not predict clinical outcome. IPTp and decreasing malaria prevalence pose challenges for the evaluation of novel interventions for malaria during pregnancy.


Assuntos
Anticorpos Antiprotozoários/sangue , Antimaláricos/uso terapêutico , Sulfatos de Condroitina/metabolismo , Malária Falciparum/prevenção & controle , Plasmodium falciparum/imunologia , Complicações Parasitárias na Gravidez/prevenção & controle , Pirimetamina/uso terapêutico , Sulfadoxina/uso terapêutico , Adolescente , Adulto , Anticorpos Antiprotozoários/imunologia , Antígenos de Superfície/imunologia , Antimaláricos/administração & dosagem , Combinação de Medicamentos , Eritrócitos/imunologia , Eritrócitos/parasitologia , Feminino , Humanos , Imunoglobulina G/sangue , Estudos Longitudinais , Malária Falciparum/imunologia , Malaui , Paridade , Gravidez , Complicações Parasitárias na Gravidez/imunologia , Pirimetamina/administração & dosagem , Sulfadoxina/administração & dosagem , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...